



		& Microbiology) MD		ugam Chopra MD (Pathology) sultant Pathologist	(Pathology)	
NAME	: Mr. DEEPAK JAIN					
AGE/ GENDER	: 41 YRS/MALE		PATIENT ID	: 1620164		
COLLECTED BY	:		REG. NO./LAB NO.	:0124092100)13	
REFERRED BY	: DR. JASMEET KAUR		REGISTRATION D A	TE : 21/Sep/2024 (08:04 AM	
BARCODE NO.	:01517379		COLLECTION DATI	1		
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	1		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AM	/IBALA CANTT				
Test Name		Value	Uni	t Biolog	jical Reference interval	
GLYCO GLYCOSYLATED HAEMOGLOBIN (HbA1c): WHOLE BLOOD by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY) ESTIMATED AVERAGE PLASMA GLUCOSE by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY) INTERPRETATION:		6.3 134.11	% mg/	4.0 - 6 /dL 60.00	- 140.00	
	AS PER AMERICAN D	ABETES ASSOC	iation (ADA):			
REFERENCE GROUP		GLYCOSYLATED HEMOGLOGIB (HBAIC) in %				
Non diabetic Adults >= 18 years		<5.7				
	At Risk (Prediabetes)		5.7 - 6.4 >= 6.5			
Diagnosing Diabetes		-	>= 6. Age > 19	-	-	
			s of Therapy:	< 7.0		
Therapeut	ic goals for glycemic control	Actions Suggested: >8.0				
		Age < 19 Years				
COMMENTS:		Goa	of therapy:	<7.5		

KOS Diagnostic Lab

(A Unit of KOS Healthcare)

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients. 2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropiate.

4.High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB. AMBALA CANTT





	Dr. Vinay Ch MD (Pathology & Chairman & Con		Dr. Yugarr MD CEO & Consultant	(Pathology)	
NAME	: Mr. DEEPAK JAIN				
AGE/ GENDER	: 41 YRS/MALE	PA	TIENT ID	: 1620164	
COLLECTED BY	:	REG. NO./LAB NO.		: 012409210013	
REFERRED BY	: DR. JASMEET KAUR	RI	EGISTRATION DATE	: 21/Sep/2024 08:04 AM	
BARCODE NO.	:01517379	CO	DLLECTION DATE	: 21/Sep/2024 05:10PM	
CLIENT CODE.	: KOS DIAGNOSTIC LAB	RI	EPORTING DATE	: 21/Sep/2024 06:20PM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	AMBALA CANTT			
Test Name		Value	Unit	Biological Reference interval	
Test Name	CLIN		Unit RY/BIOCHEMISTR	-	
Test Name		ICAL CHEMISTR		Y	
GLUCOSE FASTING (GLUCOS	ICAL CHEMISTR	RY/BIOCHEMISTR	Y	
GLUCOSE FASTING (by glucose oxidas GLUCOSE POST PRA	GLUCOS F): PLASMA	ICAL CHEMISTR E FASTING (F) AN	RY/BIOCHEMISTR ID POST PRANDIAL	Y (PP) NORMAL: < 100.0 PREDIABETIC: 100.0 - 125.0	

IN ACCORDANCE WITH AMERICAN DIABETES ASSOCIATION GUIDELINES:

KOS Diagnostic Lab

(A Unit of KOS Healthcare)

 A fasting plasma glucose below 100 mg/dL and post-prandial plasma glucose level below 140 mg/dl is considered normal.
A fasting plasma glucose level between 100 - 125 mg/dl and post-prandial plasma glucose level between 140 - 200 mg/dL is considered as glucose intolerant or pre diabetic. A fasting and post-prandial blood test (after consumption of 75 gms of glucose) is recommended for all such patients

3. A fasting plasma glucose level of above 125 mg/dL and post-prandial plasma glucose level above 200 mg/dL is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB. AMBALA CANTT





	MD	Vinay Chopra (Pathology & Microbiology) irman & Consultant Pathologi		(Pathology)
NAME	: Mr. DEEPAK JA	IN		
AGE/ GENDER	: 41 YRS/MALE		PATIENT ID	: 1620164
COLLECTED BY	:		REG. NO./LAB NO.	: 012409210013
REFERRED BY	: DR. JASMEET KA	UR	REGISTRATION DATE	: 21/Sep/2024 08:04 AM
BARCODE NO.	:01517379		COLLECTION DATE	: 21/Sep/2024 05:10PM
CLIENT CODE.	: KOS DIAGNOSTI	C LAB	REPORTING DATE	: 21/Sep/2024 07:53PM
CLIENT ADDRESS	: 6349/1, NICHOI	SON ROAD, AMBALA CANTI		
Test Name		Value	Unit	Biological Reference interva
		CLINICAL	PATHOLOGY	
	Ν	IICROALBUMIN/CREATI	NINE RATIO - RANDOM	/ URINE
MICROALBUMIN: RANDOM URINE		14.6	mg/L	0 - 25
by SPECTROPHOTOMETRY CREATININE: RANDOM URINE		77.84	mg/dL	20 - 320
by SPECTROPHOTOMETRY				
MICROALBUMIN/CREATININE RATIO -		18.76	mg/g	0 - 30
RANDOM URINE	IETRY			
by SPECTROPHOTON INTERPRETATION:-		1	1	
by SPECTROPHOTON INTERPRETATION:- PHYSIOLOGICALLY	NORMAL:	mg/L	0 - 30	
INTERPRETATION:-	NORMAL:	mg/L mg/L mg/L	0 - 30 30 - 300 > 300	

Long standing un-treated Diabetes and Hypertension can lead to renal dysfunction. 2. Diabetic nephropathy or kidney disease is the most common cause of end stage renal disease(ERSD) or kidney failure. 3. Presence of Microalbuminuria is an early indicator of onset of compromised renal function in these patients.

4. Microalbuminuria is the condition when urinary albumin excre tion is between 30-300 mg & above this it is called as macroalbuminuria, the

5.Microalbuminuria is not only associated with kidney disease but of cardiovascular disease in patients with dibetes & hypertension. 6.Microalbuminuria is not only associated with kidney disease but of cardiovascular disease in patients with dibetes & hypertension. 6.Microalbuminuria reflects vascular damage & appear to be a marker of of early arterial disease & endothelial dysfunction. **NOTE:-** *IF A PATIENT HAS = 1+ PROTEINURIA (30 mg/dl OR 300 mg/L) BY URINE DIPSTICK (URINEANALYSIS), OVERT PROTEINURIA IS PRESENT AND TESTING FOR MICROALBUMIN IS INAPPROPIATE. IN SUCH A CASE, URINE PROTEIN:CREATININE RATIO OR 24 HOURS TOTAL URINE MICROPROTEIN IS Appropriate.* APPROPIATE.

*** End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

